What is Cytek Biosciences, Inc.'s G&A?

Cytek Biosciences, Inc. (CTKB) reported G&A of $18.47M in Q1 2026.

How has Cytek Biosciences, Inc.'s G&A changed year-over-year?

Cytek Biosciences, Inc.'s G&A increased by 43.2% year-over-year, from $12.9M to $18.47M.

What is the long-term trend for Cytek Biosciences, Inc.'s G&A?

Over 4 years (2021 to 2025), Cytek Biosciences, Inc.'s G&A has grown at a 29.7% compound annual growth rate (CAGR), from $20.84M to $58.94M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Cytek Biosciences, Inc. CTKB G&A

G&A at other companies

Fulgent Genetics, Inc.FLGT

$27.68M+9.5%

HTF

Heartflow, Inc. Common StockHTFL

$12.61M+27.6%

Alto NeuroscienceANRO

$6.84M+20.0%

Other financials

Income statement

See full

Revenue$44.1M+6.5%

Gross profit$21.3M+5.4%

Operating income-$18.5M-23.3%

Net income-$18.9M-65.5%

EPS (diluted)-$0.15-66.7%

Balance sheet

See full

Cash & equivalents$31.8M-66.6%

Total debt$16.8M+40.9%

Total equity$327.6M-13.7%

Total assets$449.1M-6.9%

Cash flow

See full

Operating cash flow-$2.7M-2,089%

CapEx$2.2M+155%

Free cash flow-$4.9M-403%

Valuation

See full

Market cap$577.27M+54.5%

Enterprise value$562.23M+93.7%

P/S2.8×+0.9×

Profitability

See full

Gross margin51.7%-3.2pp

Operating margin-21.5%—

Net margin-36.2%—

FCF margin-6.2%-15.1pp

Returns & leverage

See full

Return on equity-20.9%—

Debt / equity0.1×0.0×

Current ratio4.7×-0.9×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s G&A?: Cytek Biosciences, Inc. (CTKB) reported G&A of $18.47M in Q1 2026.
How has Cytek Biosciences, Inc.'s G&A changed year-over-year?: Cytek Biosciences, Inc.'s G&A increased by 43.2% year-over-year, from $12.9M to $18.47M.
What is the long-term trend for Cytek Biosciences, Inc.'s G&A?: Over 4 years (2021 to 2025), Cytek Biosciences, Inc.'s G&A has grown at a 29.7% compound annual growth rate (CAGR), from $20.84M to $58.94M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.